Humira if I am not mistaken is listed for 6 indications.... so technically speaking we may be the biggest drug with these analysis based on one indications alone .... lol....
On a serious note, as much as I see high probability of one of the indications seeing through the final stage of FDA approval, these posts don't don't really help with decision making....
everything is step by step approach......do I think Dimerix based on future potential should now be valued at 500m? certainly not .... do I think current valuation reflects the potential .... hell no....
Guess the answers lies somewhere in the middle at this stage.....
Phase 3 clinical study in FSGS in the first half of 2021, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |